MarketPulse

OspA-based vaccine

1 articles
BenzingaBenzinga··Vandana Singh

Lyme Vaccine Setback: Valneva-Pfizer Trial Misses Primary Goal But Eyes Regulatory Path

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.
PFEVALNstock declinePhase 3 trial